Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 8Pancreatic Neoplasms 7Neoplasms 6Neoplasms, Plasma Cell 4Myelodysplastic Syndromes 4Colorectal Neoplasms 3Stomatitis 2Skin Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Myeloproliferative Disorders 2Leukemia, Myeloid, Acute 2Leukemia 2Inflammation 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Myofibroma 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Endocrine Neoplasia Type 1 1Mucositis 1Motor Activity 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Limb-girdle muscular dystrophy, type 2C 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrence × Ascorbic Acid × Clear all
NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Oncotherapeutics

Phase 1/2 Completed
45 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡